STOCK TITAN
  1. Home
  2. Sec-filings
  3. RANI
  4. [424B5] Rani Therapeutics Holdings, Inc. Prospectus Supplement (Debt Securities)

[424B5] Rani Therapeutics Holdings, Inc. Prospectus Supplement (Debt Securities)

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
424B5

Filing content is currently unavailable.

Source: View Original Filing on SEC EDGAR

Stock RANI logo
Rani Therapeutics Holdings, Inc.

NASDAQ:RANI

RANI Rankings

#5786 Ranked by Market Cap
N/A Ranked by Dividends

RANI Latest News

Aug 7, 2025
Rani Therapeutics Reports Second Quarter 2025 Financial Results; Provides Corporate Update
Jul 15, 2025
Rani Therapeutics Holdings, Inc. Announces Pricing of $3.0 Million Registered Direct Offering
Jul 14, 2025
Rani Therapeutics and ProGen Announce Late Breaking Presentation at ENDO 2025 Demonstrating Bioequivalence of Novel, Bispecific GLP-1/GLP-2 Receptor Agonist Delivered Orally via RaniPill Compared to Subcutaneous Delivery 
May 19, 2025
Rani Therapeutics Announces Research Agreement with Chugai
May 13, 2025
Rani Therapeutics Reports First Quarter 2025 Financial Results; Provides Corporate Update

RANI Latest SEC Filings

Aug 14, 2025
[SCHEDULE 13G] Rani Therapeutics Holdings, Inc. SEC Filing
Aug 8, 2025
[S-3] Rani Therapeutics Holdings, Inc. Shelf Registration Statement
Aug 7, 2025
[8-K] Rani Therapeutics Holdings, Inc. Reports Material Event
Aug 5, 2025
[Form 4] Rani Therapeutics Holdings, Inc. Insider Trading Activity
Jul 23, 2025
[SCHEDULE 13G/A] Rani Therapeutics Holdings, Inc. SEC Filing

RANI Stock Data

24.19M
38.54M
19.56%
17.01%
0.22%
Biotechnology
Pharmaceutical Preparations
Link
United States
SAN JOSE